Vivace indications
Hypertension: this medicine is indicated for the treatment of hypertension.
Heart Failure:
this medicine is indicated for the treatment of chronic heart failure with reduction of systolic ventricular function, in combination with diuretics and when appropriate, digitalis and beta-blockers.
Myocardial Infarction:
-Short -term (4 weeks) treatment: this medicine is indicated in any clinically stable patients within the first 24 hours of an infarction.
-Long term prevention of symptomatic heart failure: this medicine is indicated in clinically stable patients with asymptomatic left ventricular dysfunction (ejection fraction <40%).
Type I Diabetic Nephropathy:
this medicine is indicated for the treatment of macroproteinuric diabetic nephropathy in patients with type I diabetes..
Vivace description
A potent and specific inhibitor of peptidyl-dipeptidase A. It blocks the conversion of angiotensin I to angiotensin II, a vasoconstrictor and important regulator of arterial blood pressure. Vivace acts to suppress the renin-angiotensin system and inhibits pressure responses to exogenous angiotensin.
Vivace interactions
Hypotension ó Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril.
The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg). Alternatively, provide medical supervision for at least one hour after the initial dose. If hypotension occurs, the patient should be placed in a supine position and, if necessary, receive an intravenous infusion of normal saline. This transient hypotensive response is not a contraindication to further doses which can be given without difficulty once the blood pressure has increased after volume expansion.
Agents Having Vasodilator Activity: Data on the effect of concomitant use of other vasodilators in patients receiving captopril for heart failure are not available; therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril. If resumed during captopril therapy, such agents should be administered cautiously, and perhaps at lower dosage.
Agents Causing Renin Release
Vivaceís effect will be augmented by antihypertensive agents that cause renin release. For example, diuretics (e.g., thiazides) may activate the renin-angiotensin-aldosterone system.
Agents Affecting Sympathetic Activity
The sympathetic nervous system may be especially important in supporting blood pressure in patients receiving captopril alone or with diuretics. Therefore, agents affecting sympathetic activity (e.g., ganglionic blocking agents or adrenergic neuron blocking agents) should be used with caution. Beta-adrenergic blocking drugs add some further antihypertensive effect to captopril, but the overall response is less than additive.
Agents Increasing Serum Potassium
Since captopril decreases aldosterone production, elevation of serum potassium may occur. Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium. Salt substitutes containing potassium should also be used with caution.
Inhibitors Of Endogenous Prostaglandin Synthesis
It has been reported that indomethacin may reduce the antihypertensive effect of captopril, especially in cases of low renin hypertension. Other nonsteroidal anti-inflammatory agents (e.g., aspirin) may also have this effect.
Lithium
Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. These drugs should be coad-ministered with caution and frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, it may increase the risk of lithium toxicity.
Cardiac Glycosides
In a study of young healthy male subjects no evidence of a direct pharmacokinetic captopril-digoxin interaction could be found.
Loop Diuretics: Furosemide administered concurrently with cap-topril does not alter the pharmacokinetics of captopril in renally impaired hypertensive patients.
Allopurinol
In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when captopril and allop-urinol were administered concomitantly for 6 days.
Drug/Laboratory Test Interaction
Vivace may cause a false-positive urine test for acetone.
Vivace side effects
Undesirable effects reported for captopril and/or ACE inhibitor include:
Blood and lymphatic disorders:
Very Rare: neutropenia/agranulocytosis, pancytopenia particularly in patients with renal dysfunction, anaemia (including aplastic and haemolytic), thrombocytopenia, lymphadenopathy, eosinophilia, auto-immune diseases and/or positive ANA-titres.
Metabolism and nutrition disorders:
Rare: Anorexia
Very Rare: Hyperkalaemia, hypoglycaemia
Psychiatric disorders:
Common: Sleep disorders.
Very Rare: Confusion, depression.
Nervous system disorders:
Common: Taste impairment, dizziness.
Rare: Drowsiness, headache and paraesthesia.
Very Rare: Cerebrovascular incidents, including stroke, and syncope.
Eye disorders:
Very Rare: Blurred vision.
Cardiac disorders:
Uncommon: Tachycardia or tachyarrhythmia, angina pectoris, palpitations.
Very Rare: Cardiac arrest, cardiogenic shock.
Vascular disorders
Uncommon: Hypotension, Raynaud syndrome, flush, pallor.
Respiratory, thoracic and mediastinal disorders:
Common: Dry, irritating (non productive) cough and dyspnoea.
Very Rare: Bronchospasm, rhinitis, allergic alveolitis / eosinophilic pneumonia.
Gastrointestinal disorders:
Common: Nausea, vomiting, gastric irritations, abdominal pain, diarrhoea, constipation, dry mouth.
Rare: Stomatitis/aphthous ulcerations.
Very Rare: Glossitis, peptic ulcer, pancreatitis.
Hepato-biliary disorders:
Very Rare: Impaired hepatic function and cholestasis. (including jaundice), hepatitis including necrosis, elevated liver enzymes and bilirubin.
Skin and subcutaneous tissue disorders:
Common: Pruritus with or without a rash, rash and alopecia.
Uncommon: Angioedema
Very Rare: Urticaria, Stevens Johnson syndrome, erythema multiforme, photosensitivity, erythroderma, pemphigoid reactions and exfoliative dermatitis.
Musculoskeletal, connective tissue and bone disorders:
Very rare: Myalgia, arthralgia.
Renal and urinary disorders:
Rare: Renal function disorders including renal failure, polyuria, oliguria, increased urine frequency.
Very Rare: Nephrotic syndrome.
Reproductive system and breast disorders:
Very Rare: Impotence, gynaecomastia.
General disorders:
Uncommon: Chest pain, fatigue, malaise.
Very Rare: Fever
Investigations:
Very Rare: Proteinuria, eosinophilia, increase of serum potassium, decrease of serum sodium, elevation of BUN, serum creatinine and serum bilirubin, decreases in haemoglobin, haematocrit, leucocytes, thrombocytes, positive ANAtitre, elevated ESR.
Intestinal angioedema has also been reported very rarely in patients with ACE inhibitors and should be included in the differential diagnosis of patients on ACE inhibitors presenting with abdominal pain.
Vivace contraindications
Vivace is contraindicated in patients who are hypersensitive to this product or any other angiotensin-converting enzyme inhibitor (e.g.,a patient who has experienced angioedema during therapy with any other ACE inhibitor).
Active ingredient matches for Vivace:
Delapril/Manidipine in Germany, Greece, Spain.
Ramipril in Poland, Romania.
| Unit description / dosage (Manufacturer) | Price, USD |
| Vivace 2.5 mg x 30's | $ 15.62 |
| Vivace 5 mg x 30's | $ 24.18 |
| Vivace 10 mg x 30's | $ 37.20 |
| Vivace 3 Blister x 10 Tablet | |
| Vivace 10 Blister x 10 Tablet | |
List of Vivace substitutes (brand and generic names): | |
| Vesdil Protect | |
| Tablets; Oral; Ramipril 10 mg | |
| Vivace 30/10mg (Germany) | |
| Vivokar (Bulgaria) | |
| Winpace | |
| Winpace 5 mg Tablet (Bison Biotec Pvt Ltd) | $ 0.12 |
| Winpace 2.5 mg Tablet (Bison Biotec Pvt Ltd) | $ 0.07 |
| Winthrop Ramipril (Philippines) | |
| Winthrop Ramipril 2.5 mg x 100's | $ 27.78 |
| Winthrop Ramipril 5 mg x 100's | $ 33.33 |
| Winthrop Ramipril 10 mg x 30's | $ 14.31 |
| X PRIL | |
| X PRIL 5 MG TABLET 1 strip / 10 tablets each (Biochem Pharmaceutical Industries) | $ 0.77 |
| X Pril 5mg Tablet (Biochem Pharmaceutical Industries) | $ 0.08 |
| XYPRIL (India) | |
| 2.5 mg x 100's (Arrowin Pharmaceuticals) | $ 5.40 |
| 5 mg x 100's (Arrowin Pharmaceuticals) | $ 9.01 |
| Xypril 2.5 mg Capsule (Arrowin Pharmaceuticals) | $ 0.05 |
| Xypril 5 mg Capsule (Arrowin Pharmaceuticals) | $ 0.09 |
| Xypril 2.5mg CAP / 100 (Arrowin Pharmaceuticals) | $ 5.40 |
| Xypril 5mg CAP / 100 (Arrowin Pharmaceuticals) | $ 9.01 |
| XYPRIL cap 2.5 mg x 10's (Arrowin Pharmaceuticals) | $ 0.54 |
| XYPRIL cap 5 mg x 10's (Arrowin Pharmaceuticals) | $ 0.90 |
| Xypril 2.5mg CAP / 100 (Arrowin Pharmaceuticals) | $ 5.40 |
| Xypril 5mg CAP / 100 (Arrowin Pharmaceuticals) | $ 9.01 |
| XYPRIL-H (India) | |
| 100's (Arrowin) | $ 6.60 |
| Xypril-H Ramipril 2.5 mg, Hydrochlorothiazide 12.5 mg. CAP / 100 (Arrowin) | $ 6.60 |
| XYPRIL-H cap 10's (Arrowin) | $ 0.66 |
| Xypril-H Ramipril 2.5 mg, Hydrochlorothiazide 12.5 mg. CAP / 100 (Arrowin) | $ 6.60 |
| Zedpril (India) | |
| Zedpril 2.5mg TAB / 100 (Essweil) | |
| Zedpril 5mg TAB / 150 (Essweil) | |
| 2.5 mg x 100's (Essweil) | |
| 5 mg x 150's (Essweil) | |
| ZEDPRIL tab 2.5 mg x 10's (Essweil) | |
| ZEDPRIL tab 5 mg x 10's (Essweil) | |
| Zenra (Romania) | |
| ZIGPRIL (India) | |
| 2.5 mg x 10's (Biocon Limited) | $ 0.53 |
| 5 mg x 10's (Biocon Limited) | $ 0.99 |
| Zigpril 5 mg Capsule (Biocon Limited) | $ 0.10 |
| Zigpril 2.5 mg Capsule (Biocon Limited) | $ 0.05 |
| Zigpril 2.5mg CAP / 10 (Biocon Limited) | $ 0.53 |
| Zigpril 5mg CAP / 10 (Biocon Limited) | $ 0.99 |
| ZIGPRIL 5MG CAPSULE 1 strip / 10 capsules each (Biocon Limited) | $ 0.95 |
| ZIGPRIL cap 2.5 mg x 10's (Biocon Limited) | $ 0.53 |
| ZIGPRIL cap 5 mg x 10's (Biocon Limited) | $ 0.99 |
| Zigpril 2.5mg CAP / 10 (Biocon Limited) | $ 0.53 |
| Zigpril 5mg CAP / 10 (Biocon Limited) | $ 0.99 |
See 2189 substitutes for Vivace | |
References
- DailyMed. "RAMIPRIL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "ramipril". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- PubChem. "manidipine". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Vivace are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Vivace. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yet2 consumers reported age
| Users | % | ||
|---|---|---|---|
| > 60 | 1 | 50.0% | |
| 30-45 | 1 | 50.0% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
